Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.

Roche plans to regroup on its $4.3 billion offer to buy Spark Therapeutics after failing to win enough Spark shareholder votes, or receiving U.S. regulatory approval.

Roku was hit with a pair of downgrades on Wednesday

Jim Cramer asks whether there aren't enough good things happening that we can sustain an advance without a China deal.

ETFs could see big inflows again and Sparks stock soars; these are among the important market items today.

The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.

Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.

U.S. stock futures rise after Donald Trump says he will delay increasing tariffs on China-made goods; Swiss drug giant Roche to buy Spark Therapeutics for about $4.8 billion; Warren Buffett wants to make an 'elephant-sized acquisition'; Kraft Heinz reportedly reviewing options for Maxwell House.

Amyris is showing progress in one key area, but it may not be enough.

The disgraced investor and convicted felon launched a cryptocurrency last July after his release from prison.

The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.